Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.

Content by Novo Nordisk

Scientist in lab using pipette for liquid testing in research on oral formulation technologies.

| 2 min read

byBioMed XandNovo Nordisk

BioMed X and Novo Nordisk launch new collaboration in oral peptide drug delivery

The initiative aims to identify and support new ideas for innovative oral formulations for peptide drugs such as GLP-1 receptor agonists via BioMed X’s global talent sourcing and incubation model.

Industry Perspectives

Page 1 of 1 - 1 Total Items

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

A 3D molecular visualization of antibody-like protein structures with attached yellow payloads floating against a dark, space-like background.

Advancing bioconjugate development through innovative approaches

Evolving approaches to conjugation chemistry and linker–payload design are helping address persistent challenges in bioconjugate development.

Whitepaper

Fluorescent-style illustration of spherical embryonic stem cells clustered together against a dark background.

Advancing predictive in vitro models

Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.

Webinars